Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7809740 | 0.98 | CHRNA7 (0.40) | MAPK1CHRNA7LMNACYP2C9SLC6A2 | |
| SCHEMBL2957850 | 0.91 | MAPK1 (0.54) | MAPK1CHRNA7LMNACYP2C9CHRM3 | |
| Hydrochloric Acid SCHEMBL2957846 | 0.89 | MAPK1 (0.52) | MAPK1CHRNA7LMNACYP2C9CHRM3 | |
| Acetic Acid SCHEMBL9874813 | 0.82 | MAPK1 (0.46) | MAPK1CHRNA7SLC6A4SLC6A3CHRM3 | |
| SCHEMBL3412649 | 0.80 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL1922482 | 0.80 | CHRNA7 (0.45) | CHRNA7 | |
| SCHEMBL3410709 | 0.80 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL12022394 | 0.78 | MAPK1 (0.43) | MAPK1CHRNA7LMNACYP2C9SLC6A2 | |
| SCHEMBL3408506 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL14094910 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751196-A | Method for efficiently synthesizing maraviroc intermediate N-benzyl tropylamine | 大连万福制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | claimed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | claimed |
| CN-116751196-A | Method for efficiently synthesizing maraviroc intermediate N-benzyl tropylamine | 大连万福制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2022241188-A1 | ENANTIOSELECTIVE SYNTHESIS OF AMINOTROPANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022241188-A1 | ENANTIOSELECTIVE SYNTHESIS OF AMINOTROPANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3067352-A2 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | Cardioxyl Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2278975-B1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-4599420-A | GASTROINTESTINAL DISORDERS, ANTIEMETIC, PSYCHOSIS | BEECHAM GROUP LTD. (GB) | 1986-07-08 | — | — | US | disclosed |
| US-4544660-A | DOPAMINE ANTAGONIST | BEECHAM GROUP P.L.C. (GB) | 1985-10-01 | — | — | US | disclosed |
| WO-1984000166-A1 | BENZOIC ACID PIPERIDYL ESTER DERIVATIVES AND METHOD OF PRODUCTION AND UTILIZATION THEREOF | SANDOZ AG (CH) | 1984-01-19 | — | — | WO | disclosed |
| EP-0013138-B1 | AZABICYCLOALKYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1983-12-07 | — | — | EP | disclosed |
| EP-0081054-A2 | Azabicyclo alkyl derivatives | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| US-4336259-A | DOPAMINE ANTAGONIST, NERVOUS SYSTEM DISORDERS AND GASTROINTESTINAL DISORDERS | BEECHAM GROUP LIMITED (GB) | 1982-06-22 | — | — | US | disclosed |
| EP-0042705-A1 | Azabicycloalkane derivatives, their preparation and use | BEECHAM GROUP PLC (GB) | 1981-12-30 | — | — | EP | disclosed |
| US-4273778-A | TREATMENT OF GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, AND PSYCHOLOGICAL DISORDERS | BEECHAM GROUP, LIMITED (GB) | 1981-06-16 | — | — | US | disclosed |
| EP-0013138-A1 | Azabicycloalkyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | MAPK1 4000/4885CHRNA7 1091/4885LMNA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.